Tredegar Corporation, through its subsidiaries, manufactures and sells aluminum extrusions, polyethylene (PE) films, and plastic and polyester films in the United States and internationally. It operates through three segments: Aluminum Extrusions, PE Films, and Flexible Packaging Films. The Aluminum Extrusions segment produces soft and medium strength alloyed aluminum extrusions, custom fabricated and finished aluminum extrusions for the building and construction, automotive and transportation, consumer durables, machinery and equipment, electrical and renewable energy, and distribution markets; and manufactures mill, anodized, and painted and fabricated aluminum extrusions to fabricators and distributors. The PE Films segment offers single- and multi-layer surface protection films for protecting components of flat panel displays that are used in televisions, monitors, notebooks, smart phones, tablets, e-readers, and digital signage under the UltraMask, ForceField, ForceField PEARL, and Pearl A brands. This segment also provides thin-gauge films as overwrap for bathroom tissue and paper towels, as well as polyethylene overwrap films and films for other markets. The Flexible Packaging Films segment offers polyester-based films for food packaging and industrial applications under the Terphane, Ecophane, and Sealphane brands. Tredegar Corporation was incorporated in 1988 and is headquartered in Richmond, Virginia.

Tredegar Corporation

For Immediate Release
Chicago, IL – May 9, 2025 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: NVIDIA Corp. NVDA, Abbott Laboratories ABT and Linde plc LIN and Tredegar Corp. TG.
Here are highlights from Thursday’s Analyst Blog:
Top Stock Reports for NVIDIA, Abbott Labs and Linde
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including NVIDIA Corp., Abbott Laboratories and Linde plc, as well as a micro-cap stock Tredegar Corp.. The Zacks microcap research is unique as our research content on these small and under-the-radar companies is the only research of its type in the country.
These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.
You can see all of today's research reports here >>>
Ahead of Wall Street
The daily 'Ahead of Wall Street' article is a must-read for all investors who would like to be ready for that day's trading action. The article comes out before the market opens and attempts to make sense of that morning's economic releases and how they will affect that day's market action. You can read this article for free on our home page and can actually sign up there to get an email notification as this article comes out each morning.
You can read today's AWS here >>> Jobless Claims, Q1 Productivity Hit Multi-Year Levels
Today's Featured Research Reports
NVIDIA's shares have outperformed the Zacks Semiconductor - General industry over the past year (+31.9% vs. +24.5%). The company is benefiting from the strong growth of artificial intelligence (AI), high-performance and accelerated computing. The growing demand for generative AI and large language models using graphic processing units (GPUs) based on NVIDIA's Hopper and Blackwell architectures is aiding data center revenues.
Continued ramp-up of Ada RTX GPU workstations in the ProViz end market, following the normalization of channel inventory, is acting as a tailwind. The Zacks analyst expects NVIDIA's revenues to witness a CAGR of 27.7% through fiscal 2026-2028. Collaborations with over 320 automakers and tier-one suppliers are likely to advance its presence in the autonomous vehicles space.
However, a limited supply of Blackwell and Ada GPUs could hinder its ability to meet demand. Rising costs associated with the production of more complex AI systems will hurt margins.
(You can read the full research report on NVIDIA here >>>)
Shares of Abbott Laboratories have outperformed the Zacks Medical - Products industry over the past year (+30.5% vs. +10.1%). The company's pipeline is unlocking new growth opportunities, supporting the company's positive momentum and strong growth outlook for 2025. Freestyle Libre, Lingo and Libre Rio CGM devices are on a great trajectory. Alinity, the company's next-generation suite of systems, is a key driver in the core lab diagnostics business.
Abbott Laboratories is optimistic about its latest progress with biosimilars and expects this to significantly boost EPD sales, reportedly beginning this year. Despite softness in international pediatric arm, Abbott is regaining market share banking on strong Adult Nutrition business.
Yet, the significant runoff of COVID-19 testing-related sales is hurting Abbott's Diagnostics growth. Headwinds such as tough macro conditions and foreign exchange also add to the worry.
(You can read the full research report on Abbott Laboratories here >>>)
Linde's shares have outperformed the Zacks Chemical - Specialty industry over the past year (+5.9% vs. -2.5%). The company remains a dominant player in the industrial gas sector, delivering strong financial performance with consistent EPS growth, disciplined capital allocation, and industry-leading margins.
Linde's record $10 billion backlog ensures long-term revenue stability, while sustainability initiatives position it as a leader in low-carbon energy solutions. Strategic investments in high-return projects and small on-site contracts further reinforce its competitive edge.
However, foreign exchange headwinds, softening industrial demand in Europe & China, and regulatory uncertainties pose challenges. Also, slower growth in healthcare impacts diversification efforts. Despite these risks, LIN's strong execution, efficiency improvements, & long-term contracts position it well for sustained profitability & resilience in fluctuating market conditions.
(You can read the full research report on Linde here >>>)
Shares of Tredegar have outperformed the Zacks Chemical - Plastic industry over the past year (+30.5% vs. +10.1%). This microcap company with market capitalization of $282.47 million have $78 million Terphane divestiture in Nov 2024, plus $7 million due by Mar 2025, which lowered net leverage from 2.3X to 1.2X, bolstering financial flexibility for debt reduction and reinvestment.
Surface Protection rebounded with 57% volume growth and $19.4M EBITDA gain. The Obsidian film launch in October 2024 marks a strategic entry into automotive displays, expanding high-margin revenue. Despite a $13.3 million impairment at Clearfield, Aluminum Extrusions' EBITDA rose $3.4 million, with diverse end-markets buffering cyclicality. Gross margin improved to 16.1% on operational gains.
However, risks persist, such as cyclical exposure in non-residential construction and auto sectors weighing on visibility; PE Films faces customer concentration and tech disruption risks; regulatory compliance burdens could stress cash flows.
(You can read the full research report on Tredegar here >>>)
Why Haven't You Looked at Zacks' Top Stocks?
Since 2000, our top stock-picking strategies have blown away the S&P's +7.7% average gain per year. Amazingly, they soared with average gains of +48.4%, +50.2% and +56.7% per year.
Today you can access their live picks without cost or obligation.
See Stocks Free >>
Media Contact
Zacks Investment Research
800-767-3771 ext. 9339
https://www.zacks.com
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit https://www.zacks.com/performance for information about the performance numbers displayed in this press release.
Zacks' Research Chief Names "Stock Most Likely to Double"
Our team of experts has just released the 5 stocks with the greatest probability of gaining +100% or more in the coming months. Of those 5, Director of Research Sheraz Mian highlights the one stock set to climb highest.
This top pick is among the most innovative financial firms. With a fast-growing customer base (already 50+ million) and a diverse set of cutting edge solutions, this stock is poised for big gains. Of course, all our elite picks aren’t winners but this one could far surpass earlier Zacks’ Stocks Set to Double like Nano-X Imaging which shot up +129.6% in little more than 9 months.
Free: See Our Top Stock And 4 Runners Up
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Abbott Laboratories (ABT) : Free Stock Analysis Report
NVIDIA Corporation (NVDA) : Free Stock Analysis Report
Linde PLC (LIN) : Free Stock Analysis Report
This article originally published on Zacks Investment Research (zacks.com).
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

The Zacks Analyst Blog Highlights NVIDIA, Abbott Laboratories, Linde and Tredegar

Thursday, May 8, 2025
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including NVIDIA Corp. (NVDA), Abbott Laboratories (ABT) and Linde plc (LIN), as well as a micro-cap stock Tredegar Corp. (TG). The Zacks microcap research is unique as our research content on these small and under-the-radar companies is the only research of its type in the country.
These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.
You can see all of today’s research reports here >>>
Ahead of Wall Street
The daily 'Ahead of Wall Street' article is a must-read for all investors who would like to be ready for that day's trading action. The article comes out before the market opens and attempts to make sense of that morning's economic releases and how they will affect that day's market action. You can read this article for free on our home page and can actually sign up there to get an email notification as this article comes out each morning.
You can read today's AWS here >>> Jobless Claims, Q1 Productivity Hit Multi-Year Levels
Today's Featured Research Reports
NVIDIA’s shares have outperformed the Zacks Semiconductor - General industry over the past year (+31.9% vs. +24.5%). The company is benefiting from the strong growth of artificial intelligence (AI), high-performance and accelerated computing. The growing demand for generative AI and large language models using graphic processing units (GPUs) based on NVIDIA’s Hopper and Blackwell architectures is aiding data center revenues.
Continued ramp-up of Ada RTX GPU workstations in the ProViz end market, following the normalization of channel inventory, is acting as a tailwind. The Zacks analyst expects NVIDIA’s revenues to witness a CAGR of 27.7% through fiscal 2026-2028. Collaborations with over 320 automakers and tier-one suppliers are likely to advance its presence in the autonomous vehicles space.
However, a limited supply of Blackwell and Ada GPUs could hinder its ability to meet demand. Rising costs associated with the production of more complex AI systems will hurt margins.
(You can read the full research report on NVIDIA here >>>)
Shares of Abbott Laboratories have outperformed the Zacks Medical - Products industry over the past year (+30.5% vs. +10.1%). The company’s pipeline is unlocking new growth opportunities, supporting the company’s positive momentum and strong growth outlook for 2025. Freestyle Libre, Lingo and Libre Rio CGM devices are on a great trajectory. Alinity, the company’s next-generation suite of systems, is a key driver in the core lab diagnostics business.
Abbott Laboratories is optimistic about its latest progress with biosimilars and expects this to significantly boost EPD sales, reportedly beginning this year. Despite softness in international pediatric arm, Abbott is regaining market share banking on strong Adult Nutrition business.
Yet, the significant runoff of COVID-19 testing-related sales is hurting Abbott’s Diagnostics growth. Headwinds such as tough macro conditions and foreign exchange also add to the worry.
(You can read the full research report on Abbott Laboratories here >>>)
Linde’s shares have outperformed the Zacks Chemical - Specialty industry over the past year (+5.9% vs. -2.5%). The company remains a dominant player in the industrial gas sector, delivering strong financial performance with consistent EPS growth, disciplined capital allocation, and industry-leading margins.
Linde’s record $10 billion backlog ensures long-term revenue stability, while sustainability initiatives position it as a leader in low-carbon energy solutions. Strategic investments in high-return projects and small on-site contracts further reinforce its competitive edge.
However, foreign exchange headwinds, softening industrial demand in Europe & China, and regulatory uncertainties pose challenges. Also, slower growth in healthcare impacts diversification efforts. Despite these risks, LIN's strong execution, efficiency improvements, & long-term contracts position it well for sustained profitability & resilience in fluctuating market conditions.
(You can read the full research report on Linde here >>>)
Shares of Tredegar have outperformed the Zacks Chemical - Plastic industry over the past year (+30.5% vs. +10.1%). This microcap company with market capitalization of $282.47 million have $78 million Terphane divestiture in Nov 2024, plus $7 million due by Mar 2025, which lowered net leverage from 2.3X to 1.2X, bolstering financial flexibility for debt reduction and reinvestment.
Surface Protection rebounded with 57% volume growth and $19.4M EBITDA gain. The Obsidian film launch in October 2024 marks a strategic entry into automotive displays, expanding high-margin revenue. Despite a $13.3 million impairment at Clearfield, Aluminum Extrusions’ EBITDA rose $3.4 million, with diverse end-markets buffering cyclicality. Gross margin improved to 16.1% on operational gains.
However, risks persist, such as cyclical exposure in non-residential construction and auto sectors weighing on visibility; PE Films faces customer concentration and tech disruption risks; regulatory compliance burdens could stress cash flows.
(You can read the full research report on Tredegar here >>>)
Other noteworthy reports we are featuring today include Citigroup Inc. (C), CME Group Inc. (CME) and Constellation Energy Corp. (CEG).
Mark Vickery
Senior Editor
Note: Sheraz Mian heads the Zacks Equity Research department and is a well-regarded expert of aggregate earnings. He is frequently quoted in the print and electronic media and publishes the weekly Earnings Trends and Earnings Preview reports. If you want an email notification each time Sheraz publishes a new article, please click here>>>
Today's Must Read
NVIDIA (NVDA) Rides on Strong Adoption of GPUs, Partnerships
Abbott (ABT) EPD Gains in Emerging Space on Branded Generics
Linde's (LIN) Long-Term Contracts With Minimum Volume Aid
Featured Reports
Citigroup's (C) Streamlining Efforts Aid Amid Rising Costs
The Zacks analyst views Citigroup's efforts to grow core businesses by streamlining operations as impressive. Yet, revamping technology and risk management frameworks might flare up Costs.
Focus on Renewable Energy Aid Constellation Energy (CEG)
Per the Zacks analyst, Constellation Energy gains from expansion of renewable portfolio. Its position as an industry leader in the safe operation of nuclear plants helps it increase its nuclear output
Solid Expansion Projects to Aid Teck (TECK) Amid High Costs
Per the Zacks analyst, Teck Resources is poised well to gain from its solid expansion project pipeline despite cost pressures.
Trimble (TRMB) Benefits from Strong Recurring Revenue Growth
Per the Zacks analyst, Trimble benefits from strong growth in its recurring revenue streams, particularly in its AECO and Field Systems segments.
Leasing Aids Regency Centers (REG) Amid E-Commerce Adoption
Per the Zacks Analyst, Regency Centers is to gain from healthy leasing activity aiding occupancy and rent growth, key investments and a focus on essential retail assets. Yet, e-commerce adoption ails.
Ensign Group's (ENSG) Strategic Buyouts Aid Amid High Costs
Per the Zacks analyst, Ensign Group's expertise in acquiring healthcare-related real estate and transforming them into market leaders are commendable. Yet, rising costs weigh on margins.
Investments & Expanding Customer Base Aid ONE Gas (OGS)
Per the Zacks analyst, ONE Gas' capital expenditure should improve pipeline integrity and boost its performance. Rising demand from an expanding customer base should further boost the top line.
New Upgrades
Improving Clearing and Transaction Fees Aid CME Group (CME)
Per the Zacks analyst, CME Group is set to grow on higher clearing and transaction fees as market position, diverse derivative product lines and expansion of futures products drive volumes.
Bandwidth (BAND) Rides on Solid Demand, Strategic Collaboration
Per the Zacks analyst, healthy traction for Bandwidth's communication services in multiple sectors such as healthcare, IT services, retail and fintech will likely drive its top line.
AngioDynamics (ANGO) Rises on NanoKnife, Product Strength
Per the Zacks Analyst, AngioDynamics' strong NanoKnife momentum, deep focus on the pancreatic cancer market, and an expanding, robust product pipeline position it well for sustained long-term growth.
New Downgrades
Economic Uncertainty & High Labor Costs Hit Allegiant (ALGT)
The Zacks analyst is worried about the high labor costs at Allegiant. High costs are hurting the bottom line. Tariff-induced uncertainty adds to its woes.
Macroeconomic Pressures to Hurt Carter's (CRI) Top Line
Per the Zacks analysts, inflation, elevated interest rates and weakening consumer confidence are likely to hurt Carter's top line. The company is seeing reduced demand across segments.
Dismal Contract Sales Hurt Marriott Vacations (VAC) Prospects
Per the Zacks analyst, Marriott Vacations operations are likely to be hurt by dismal contract sales and fall in VPG. Also, an uncertain macro environment and elevated expenses are a headwind.
7 Best Stocks for the Next 30 Days
Just released: Experts distill 7 elite stocks from the current list of 220 Zacks Rank #1 Strong Buys. They deem these tickers "Most Likely for Early Price Pops."
Since 1988, the full list has beaten the market more than 2X over with an average gain of +23.9% per year. So be sure to give these hand picked 7 your immediate attention.
See them now >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Citigroup Inc. (C) : Free Stock Analysis Report
Abbott Laboratories (ABT) : Free Stock Analysis Report
CME Group Inc. (CME) : Free Stock Analysis Report
Constellation Energy Corporation (CEG) : Free Stock Analysis Report
NVIDIA Corporation (NVDA) : Free Stock Analysis Report
Tredegar Corporation (TG) : Free Stock Analysis Report
Linde PLC (LIN) : Free Stock Analysis Report
This article originally published on Zacks Investment Research (zacks.com).
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Top Stock Reports for NVIDIA, Abbott Laboratories & Linde

(RTTNews) - Tredegar Corporation (TG) Wednesday announced that Brazil's Administrative Council for Economic Defense has approved a merger control agreement allowing Tredegar to proceed with the sale of Terphane, its flexible packaging business headquartered in Brazil, to Oben Group.
The conditions contained in the merger control agreement, mainly comprised of post-closing commitments for Oben to address certain competition concerns, are expected to be met with the closing of the transaction planned for November 1, 2024.
On September 1, 2023, Tredegar entered into an agreement to sell Terphane to Oben for a net cash-free and debt-free base consideration of $116 million.
Tredegar is an industrial manufacturer with three primary businesses: custom aluminum extrusions for the North American building & construction, automotive and specialty end-use markets; surface protection films for high technology applications in the global electronics industry; and specialized polyester films primarily for the Latin American flexible packaging market.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Brazil Approves Sale Of Tredegar's Terphane Biz To Oben Group

Wednesday, September 25, 2024
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Broadcom Inc. (AVGO), Novo Nordisk A/S (NVO) and ConocoPhillips (COP), as well as two micro-cap stocks Smith-Midland Corp. (SMID) and Tredegar Corp. (TG). The Zacks microcap research is unique as our research content on these small and under-the-radar companies is the only research of its type in the country.
These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.
You can see all of today’s research reports here >>>
Broadcom’s shares have outperformed the Zacks Electronics - Semiconductors industry over the year-to-date period (+58.9% vs. +31.6%). The company is benefiting from strong demand for its networking products. In second-quarter 2024, it witnessed strong demand for custom AI accelerators, AI networking solutions, Ethernet switching, optical lasers, thin dies, PCI Express switches and Network Interface Cards from hyperscale customers.
Its solutions are suitable for addressing the needs of an increasing AI workload and the growing need for fast networking in data centers. The acquisition of VMware has benefited Infrastructure software solutions. Its expanding clientele, which includes the likes of Alphabet and Meta Platforms, is noteworthy.
AVGO’s strong partner base, including Arista Networks, Dell Technologies, Juniper and Supermicro, has been a key catalyst. AI revenues are now expected to be $12 billion for fiscal 2024.
(You can read the full research report on Broadcom here >>>)
Shares of Novo Nordisk have outperformed the Zacks Large Cap Pharmaceuticals industry over the past year (+39.4% vs. +28.1%). The company’s diabetes drugs Ozempic and Rybelsus and obesity drug Wegovy are performing well, fueled by increasing demand. Label expansions of the same in cardiovascular and other indications will likely boost sales.
It has been tackling the supply constraints of Wegovy by making serious investments in increasing its manufacturing capabilities. The drug is now indicated in the United States and the EU to also reduce heart risks, which is a huge boost. The positive recommendation in the EU for approval of Wegovy to treat heart failure is also encouraging.
However, the CRL for insulin icodec in the United States is a setback for the company. Intense rivalry in the obesity sector also threatens Novo Nordisk’s market share. Patent expiry, pricing pressure across the diabetes market and the pipeline setbacks remain a woe.
(You can read the full research report on Novo Nordisk here >>>)
ConocoPhillips’s have underperformed the Zacks Oil and Gas - Integrated - United States industry over the past year (-7.6% vs. -6.8%). The company’s significant dependence on crude oil makes it vulnerable to market fluctuations. On the cost front, inflationary pressures contribute to a projected 8.1% increase in production and operating expenses for the third quarter, thereby squeezing margins.
Nevertheless, ConocoPhillips is set to leverage its extensive untapped drilling locations in cost-effective and diverse upstream assets like Eagle Ford shale, Permian Basin and Bakken shale. The impending acquisition of Marathon Oil Corporation should boost ConocoPhillips' production capabilities and expand its regional footprint in these key regions.
It is strategically increasing its presence in the liquefied natural gas market to meet the growing energy transition demand toward a low-carbon future. ConocoPhillips’ minimal debt exposure provides resilience during periods of low commodity prices.
(You can read the full research report on ConocoPhillips here >>>)
Shares of Smith-Midland have outperformed the Zacks Building Products - Concrete and Aggregates industry over the past year (+85.6% vs. +28.3%). This microcap company with market capitalization of $192.07 million has demonstrated record revenue growth, driven by increased production volumes across its plants, especially for infrastructure-related projects. In the second quarter of 2024, revenues surged 34% year over year to $19.6 million, with a strong $59.2 million backlog supporting continued expansion.
The utility segment also showed robust growth, particularly in the Northern Virginia market. The company is strategically positioned with key infrastructure contracts and a solid financial footing, including $7.3 million in cash and a low debt-to-capitalization ratio.
However, concerns include revenue concentration, fluctuating demand in key product lines, exposure to inflation, operational risks and seasonal variability. Rising accounts receivable and the suspension of dividends could strain the company’s cash flow and impact investor sentiment.
(You can read the full research report on Smith-Midland here >>>)
Tredegar’s shares have outperformed the Zacks Chemical - Plastic industry over the past year (+37.0% vs. +19.2%). This microcap company with market capitalization of $248.82 million marked a notable recovery in the first half of 2024 by posting $15.9 million in net income from ongoing operations, a drastic rise from the previous year’s $0.5 million. Enhanced operational efficiencies doubled the EBITDA in the PE Films segment to $17 million.
Streamlined costs helped achieve $72.1 million in EBITDA. Benefiting from favorable U.S. trade policies, Tredegar expects continued market share growth in aluminum extrusions, particularly from the construction sector. The strategic sale of the Terphane unit aligns with its focus on core areas, potentially generating $85 million for reinvestment. Continuous innovation, particularly in PE Films, targets high-tech packaging demands.
However, challenges persist with weak demand in Bonnell Aluminum’s primary markets and economic sensitivity in non-residential construction, compounded by high financial leverage and a suspended dividend.
(You can read the full research report on Tredegar here >>>)
Other noteworthy reports we are featuring today include Manulife Financial Corp. (MFC), The Hershey Co. (HSY) and Alexandria Real Estate Equities, Inc. (ARE).
Mark Vickery
Senior Editor
Note: Sheraz Mian heads the Zacks Equity Research department and is a well-regarded expert of aggregate earnings. He is frequently quoted in the print and electronic media and publishes the weekly Earnings Trends and Earnings Preview reports. If you want an email notification each time Sheraz publishes a new article, please click here>>>
Today's Must Read
Strong Demand for Networking Products Aids Broadcom (AVGO)
GLP-1 Drugs Boost Novo Nordisk (NVO), Market Rivalry a Woe
ConocoPhillips' (COP) Prime Untapped Drilling Locations Aid
Featured Reports
Solid Asia Operation Aid Manulife (MFC), High Expenses Ail
Per the Zacks analyst, Manulife is set to grow on strong Asian business as well as expansion of Wealth and Asset Management business. However, increase in expenses weighing on margin concern.
Hershey (HSY) Gains on Solid North America Salty Snacks Unit
Per the Zacks analyst, strength in Hershey's North America Salty Snacks unit keeps it well positioned. Management expects mid-single-digit sales growth in this segment in 2024, fueled by innovation.
Rising Demand for Life-Science Assets Aids Alexandria (ARE)
Per the Zacks Analyst, Alexandria's premium properties are poised to experience solid demand amid the rising demand for life science assets, though a huge development pipeline raises concern.
Strong Product Portfolio Buoys Optimism for Baxter (BAX)
Per the Zacks analysts, Baxter International is well poised for growth backed by a strong product portfolio. Introduction of new therapies and products likely to drive the topline growth.
Restructuring Program to Aid CNH, Rising Debt Level Ails
Per the Zacks analyst, with its strategic restructuring program in place, CNH is likely to save in the second half of 2024. However, the rising debt level remains concerning.
Federal Realty (FRT) to Ride on Strong Retail Assets Demand
Per the Zacks Analyst, strong demand for retail assets and Federal Realty's focus on essential retail and mixed-use properties augur well, though higher e-commerce adoption is a concern.
Unit Expansion Aid Choice Hotels (CHH) Amid Inflation Woes
Per the Zacks analyst, Choice Hotels benefits from its unit growth strategy, hotel conversions and franchise business. However, uncertain macroeconomic environments are a concern.
New Upgrades
Sprouts Farmers' (SFM) Omnichannel Offering to Propel Sales
Per the Zacks analyst, Sprouts Farmers' assortment of better-for-you products focus on providing hassle-free shopping through omnichannel offering and a network of fresh distribution centers bode well
Rosy Air-Travel Demand Boosts Alaska Air's (ALK) Prospects
The Zacks analyst is pleased with the upbeat air-travel demand scenario. Alaska Air's efforts to modernize its fleet also bode well.
Yelp (YELP) Benefits from Increasing Advertising Revenues
Per the Zacks analyst, increase in the number of paying advertising locations and improved productivity from advertising sales force are bolstering Yelp's ad revenues.
New Downgrades
Clean Fuel Use, Strict Regulations Ail Arch Resources (ARCH)
Per the Zacks analyst, Arch Resources' prospects will be impacted by increasing usage of clean sources of energy and strict regulations in connection with coal mining.
Elevated Crude Prices to Hurt Eni's (E) Refining Margins
Per the Zacks analyst, elevated oil prices may hurt Eni's profitability by raising its refining business's input expenses. The company's significant exposure to debt capital also adds to the concern.
Forex Woes, Soft Sensing Solutions Business Ail Sensata (ST)
Per the Zacks analyst, Sensata's performance is affected by a weak Sensing solutions segment and forex headwinds. High-debt burden is an added concern.
7 Best Stocks for the Next 30 Days
Just released: Experts distill 7 elite stocks from the current list of 220 Zacks Rank #1 Strong Buys. They deem these tickers "Most Likely for Early Price Pops."
Since 1988, the full list has beaten the market more than 2X over with an average gain of +23.7% per year. So be sure to give these hand picked 7 your immediate attention.
See them now >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 5 Stocks Set to Double. Click to get this free report
ConocoPhillips (COP) : Free Stock Analysis Report
Novo Nordisk A/S (NVO) : Free Stock Analysis Report
Hershey Company (The) (HSY) : Free Stock Analysis Report
Manulife Financial Corp (MFC) : Free Stock Analysis Report
Broadcom Inc. (AVGO) : Free Stock Analysis Report
Alexandria Real Estate Equities, Inc. (ARE) : Free Stock Analysis Report
Tredegar Corporation (TG) : Free Stock Analysis Report
Smith-Midland Corp. (SMID): Free Stock Analysis Report
To read this article on Zacks.com click here.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.